Extended Data Fig. 1: HER2 status between matched archive and fresh biopsy samples. | Nature Medicine

Extended Data Fig. 1: HER2 status between matched archive and fresh biopsy samples.

From: Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial

Extended Data Fig. 1: HER2 status between matched archive and fresh biopsy samples.

Freq, frequency; HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; ISH, in situ hybridization; T-DXd, trastuzumab deruxtecan. All samples (fresh and archival) were taken before T-DXd treatment. There were 41 samples included in this analysis. Two of the 41 paired samples were collected from non-matched sites. One archive sample was collected from ‘other’ as the site; this sample had a HER2 IHC status change from HER2 1+ to HER2 2 + /ISH−. Another archive sample was collected from liver as the site; this sample did not have a HER2 IHC status change (HER2 IHC 3+ to HER2 IHC 3+).

Back to article page